医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

交易中 05-18 11:33:19

968.223

-23.882

-2.41%

最高993.626	最低966.860	成交量2,910万
今开992.105	昨收992.105	日振幅2.70%
总市值0.00	流通市值0.00	总股本0.00
成交额2.91亿	换手率--	流通股本0.00
市净率1.284145	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":968.22296,"timestamp":1779075198254,"preClose":992.1054,"halted":0,"volume":29103130,"delay":0,"changeRate":-0.024072,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-23.882446,"latestTime":"05-18 11:33:19","open":992.1054,"high":993.6264,"low":966.85974,"amount":290671423,"amplitude":0.02698,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1779076800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1779067800000,1779076800000],[1779080400000,1779091200000]],"pbRate":1.284145,"peRate":11.558689,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593/wiki","defaultTab":"wiki","newsList":[{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","LU1794554557.SGD","BK1600","06978","BK1587","LU0348735423.USD","09926","LU0417516902.SGD","LU2778985437.USD","BK1583","06855","SG9999014674.SGD","BK1593","LU2488822045.USD","09995","IE00B543WZ88.USD","LU0540923850.HKD","02410","LU2476274308.USD","LU1961090484.USD","BK1515","02268","BK1161","IE00B5MMRT66.SGD","LU1969619763.USD","BK1574","LU0348767384.USD","BK1191","LU0348766576.USD","LU0348825331.USD","BK1141","159992","LU1720050803.USD","LU2328871848.SGD","LU2476274720.SGD","LU0348827113.USD","LU0561508036.HKD","IE00BPRC5H50.USD","01672","LU0348784397.USD","LU0417516738.SGD","LU0634319403.HKD","00460","LU0417516571.SGD","LU2399975544.HKD","LU0348783233.USD","159938","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636932470","title":"昊海生物科技于5月15日斥资78.8万港元回购3.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2636932470","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636932470?lang=zh_cn&edition=full","pubTime":"2026-05-17 11:25","pubTimestamp":1778988300,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　昊海生物科技（06826）发布公告，于2026年5月15日斥资78.8万港元回购3.6万股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-17/doc-inhyekzs1720476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06826","BK1593","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636061617","title":"每周股票复盘：复星医药（600196）获阿尔茨海默病新药全球开发选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2636061617","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636061617?lang=zh_cn&edition=full","pubTime":"2026-05-17 01:56","pubTimestamp":1778954171,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，复星医药报收于24.13元，较上周的24.82元下跌2.78%。本周，复星医药5月12日盘中最高价报25.62元。本周关注点来自公司公告汇总：复星医药产业获授AR1001分子用于治疗阿尔茨海默病的全球多中心III期临床试验后90天内独家选择权。来自公司公告汇总：复星医药控股子公司桃红四物汤颗粒注册申请获国家药监局受理。协议涉及选择权费6000万美元，后续首付款及里程碑付款最高达1.8亿美元，另按销售分成支付。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600196","BK0096","BK0196","02196","BK1515","BK0060","BK0183","BK1593","BK0012","BK1191","BK0187","BK0175","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635208430","title":"复星医药：公司开展许可类交易遵循市场化规律","url":"https://stock-news.laohu8.com/highlight/detail?id=2635208430","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635208430?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:00","pubTimestamp":1778846400,"startTime":"0","endTime":"0","summary":"证券日报网讯5月15日，复星医药在互动平台回答投资者提问时表示，公司开展许可类交易遵循市场化规律，近年来开展的重大许可交易的对方均非大股东及其关联方。如后续涉及关联交易，公司会遵照相关法律法规及股票上市地监管要求，履行必要的前置评估/估值程序，根据《公司章程》提请相应的审批机构审议，并依照股票上市地规则进行相应披露。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739146511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK0096","BK0183","BK0012","BK0187","BK0188","BK0196","BK0175","BK1515","BK0239","BK0060","600196","02196","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635083481","title":"复星医药：星曜坤泽系由公司联营公司复健资本旗下基金所孵化的企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083481","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635083481?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:12","pubTimestamp":1778839954,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：您好，尊敬的复兴医药董秘。我是复兴医药的一名普通投资者，请问贵公司与苏州星耀坤泽是否有关联？有的话占比多少？该公司现在101及102药物研发进展如何？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739069829.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739069829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0239","BK1515","BK1593","BK0196","BK0187","600196","BK0028","02196","BK0188","BK0175","BK0060","BK0183","BK0012","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635908882","title":"复星医药：目前控股子公司复宏汉霖已收到与Eisai合作项下的首付现金款","url":"https://stock-news.laohu8.com/highlight/detail?id=2635908882","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635908882?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:47","pubTimestamp":1778838457,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：董秘您好，请问：复宏汉霖2026年2月授权卫材的7500万美元首付款，在复星医药2026年一季度合并报表中，是否已确认为当期收入？谢谢。复星医药（600196.SH）5月15日在投资者互动平台表示，截至目前，控股子公司复宏汉霖已收到与Eisai合作项下的首付现金款，并根据会计准则进行会计处理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153739043716.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153739043716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","02696","BK1191","HK0000320264.USD","HK0000306685.HKD","BK0175","BK1593","BK0096","BK0060","600196","BK1515","HK0000320223.HKD","BK0183","BK0028","BK1161","HK0000306701.USD","HK0000165453.HKD","BK0188","BK0196","02196","BK0187","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635770714","title":"昊海生物科技(06826)5月15日斥资78.8万港元回购3.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635770714","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635770714?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:23","pubTimestamp":1778837017,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2026年5月15日斥资78.8万港元回购3.6万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635704030","title":"时代天使(06699)委任陈曦为公司秘书及授权代表","url":"https://stock-news.laohu8.com/highlight/detail?id=2635704030","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635704030?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:41","pubTimestamp":1778834515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，时代天使(06699)公布，李亮贤已辞任公司秘书及授权代表，陈曦女士已获委任为公司秘书及授权代表，自2026年5月15日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","06699","BK1583","BK1593","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635743879","title":"复星医药再加码阿尔茨海默病口服药，预计年内出三期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2635743879","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635743879?lang=zh_cn&edition=full","pubTime":"2026-05-14 21:33","pubTimestamp":1778765580,"startTime":"0","endTime":"0","summary":"“昨天我们刚刚达成协议，今天早上双方团队开始融合了，会以更大的投入来加速整体的完成速度。全球加起来有十几个国家参与，200多个不同的医院参与，所以整个数据清理需要花一点时间，预计今年9-10月份可能出三期数据，到年底，也许能知道这个药是否可以递交NDA（新药申请）。”5月14日，复星医药（600196.SH，2196.HK）联席总裁王兴利在媒体沟通会上透露了上述消息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143737752528.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737752528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","BK1515","BK0239","BK0188","BK0012","BK0060","BK1593","BK0183","BK0187","BK0196","BK0175","600196","02196","BK0096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635171861","title":"复星医药的“聪明Deal”：6000万美元锁住AR1001超25亿美元想象空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2635171861","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635171861?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:44","pubTimestamp":1778751861,"startTime":"0","endTime":"0","summary":"然而，复星医药选择的AR1001走了一条差异化的道路——小分子口服药物。复星医药本次先向AriBio支付6000万美元的选择权费，这笔钱买的是“看涨期权”，复星医药拥有一个约定的行权窗口期，可以在这段时间内从容等待AR1001的全球III期临床试验顶线结果。一旦III期结果积极，选择行权，此时再支付8000万美元的首付款，等到上市，再支付1亿美元的监管里程碑付款。这一次，复星医药拿下的不仅是“卖药的权利”，赢得认可的更是“造药出海的能力”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","600196","BK0096","BK0196","02196","BK1515","BK0060","BK0183","BK1593","BK0012","BK1191","BK0187","BK0175","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635882763","title":"时代天使(06699)胜诉 欧洲法院驳回爱齐科技专利侵权指控","url":"https://stock-news.laohu8.com/highlight/detail?id=2635882763","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635882763?lang=zh_cn&edition=full","pubTime":"2026-05-14 09:24","pubTimestamp":1778721851,"startTime":"0","endTime":"0","summary":"5月12日，时代天使(06699)表示，对于统一专利法院德国杜塞尔多夫地方分院驳回爱齐科技要求时代天使停止使用A7拔除前磨牙解决方案的请求，公司对此表示感谢。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260514/20260514092500_26262.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260514/20260514092500_26262.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"时代天使(06699)胜诉 欧洲法院驳回爱齐科技专利侵权指控","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1100","06699","BK1587","BK1593","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635542847","title":"国家医保局：持续创新拓展“人工智能+医保监管”的实践路径和应用场景；复星医药控股子公司获AriBio授予独家选择权丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2635542847","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635542847?lang=zh_cn&edition=full","pubTime":"2026-05-14 07:04","pubTimestamp":1778713480,"startTime":"0","endTime":"0","summary":"丨2026年5月14日星期四丨NO.1国家医保局：持续创新拓展“人工智能+医保监管”的实践路径和应用场景5月13日，国家医疗保障局印发《医疗保障基金监督检查五年行动计划（2026年—2030年）》。行动计划提出，聚焦人工智能赋能，持续创新拓展“人工智能+医保监管”的实践路径和应用场景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143736403322.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143736403322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0096","BK0012","159938","BK0060","BK1191","BK1161","BK1574","AGIX","BK0187","BK0188","BK0196","CHAT","BK0028","02196","BK0183","161631","09939","600196","BK0239","ARTY","BK1515","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635057789","title":"复星医药(02196)：桃红四物汤颗粒的药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2635057789","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635057789?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:30","pubTimestamp":1778671817,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，上海复星医药(集团)股份有限公司控股子公司河北万邦复临药业有限公司就桃红四物汤颗粒的药品注册申请获国家药品监督管理局受理。截至本公告日期，仅两款桃红四物汤颗粒于中国境内获批上市，获批时间分别为2025年4月、2026年4月，目前尚未能从IQVIA CHPA查询到该等药品2025年于中国境内的销售额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0012","BK0188","BK0060","BK0196","BK1191","02196","BK0183","600196","BK0028","BK1515","BK0175","BK0187","BK0239","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184425360","title":"复星医药旗下桃红四物汤颗粒药品注册申请获中国药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1184425360","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184425360?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:27","pubTimestamp":1778671633,"startTime":"0","endTime":"0","summary":"复星医药旗下单位提交的桃红四物汤颗粒药品注册申请，已获得中国国家药品监督管理局正式受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0096","BK0183","BK0012","BK0187","BK0188","BK0196","BK0175","BK1515","BK0239","BK0060","600196","02196","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635785407","title":"复星医药最新公告：控股子公司复星医药产业获AriBio授予独家选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=2635785407","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635785407?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:51","pubTimestamp":1778669467,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司复星医药产业与AriBio签订独家选择权协议，获授许可产品AR1001(用于治疗早期阿尔茨海默病)的全球多中心III期临床试验完成后90天内决定是否行权的权利。如行权，将获授权在全球范围(特定区域除外)独家开发、注册、生产及商业化该药物。复星医药产业需支付6000万美元选择权费，行权后另付至多1.8亿美元首付款及监碑款项。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300035413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0096","BK1191","BK1515","600196","BK1593","BK0028","BK0239","BK0060","BK0175","BK0188","BK0183","BK0012","02196","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635832517","title":"四环医药(00460)5月13日斥资1093.1万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635832517","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635832517?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:37","pubTimestamp":1778668627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2026年5月13日斥资1093.1万港元回购1000万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","00460","BK1600","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635681202","title":"昊海生物科技(06826)5月13日斥资70.33万港元回购3.15万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635681202","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635681202?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:07","pubTimestamp":1778663269,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，该公司于2026年5月13日斥资70.33万港元回购3.15万股股份，每股回购价格为22.08-22.46港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634402283","title":"昊海生物科技(06826)5月11日斥资99.73万港元回购4.37万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634402283","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634402283?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:56","pubTimestamp":1778493365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2026年5月11日，该公司斥资99.73万港元回购4.37万股股份，每股回购价22.72-22.86港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","BK1161","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634441253","title":"复星医药子公司HLX05-N获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634441253","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634441253?lang=zh_cn&edition=full","pubTime":"2026-05-10 16:03","pubTimestamp":1778400218,"startTime":"0","endTime":"0","summary":"5月10日晚间，复星医药（600196）发布公告称，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司（以下合称“复宏汉霖”）获美国FDA（即美国食品药品监督管理局）批准开展HLX05-N（即重组抗EGFR人鼠嵌合单克隆抗体注射液）用于转移性结直肠癌治疗的Ⅰ期临床试验。复宏汉霖拟于条件具备后于美国开展该药品的相关临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605103732389587.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605103732389587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK0096","BK4585","BK0060","BK0196","BK1191","BK0187","BK0028","BK1593","LABU","600196","BK0188","BK1515","02196","BK0175","BK0239","BK0183","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634144162","title":"复星医药最新公告：斯鲁利单抗注射液新增适应症获欧盟批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634144162","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634144162?lang=zh_cn&edition=full","pubTime":"2026-05-10 15:40","pubTimestamp":1778398852,"startTime":"0","endTime":"0","summary":"复星医药公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液新增两项适应症获欧盟委员会批准，分别为联合化疗一线治疗PD-L1CPS≥5的不可切除局部晚期、复发或转移性食管鳞状细胞癌成人患者，以及联合化疗一线治疗EGFR基因突变阴性、ALK或ROS1阴性的不可手术切除局部晚期或转移性非鳞状非小细胞肺癌成人患者。该药品此前已在欧盟获批用于广泛期小细胞肺癌一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000002617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","02196","BK0028","FSXEmain","BK0175","BK0196","600196","BK0012","BK0187","BK1593","BK0096","BK0239","BK1191","FESXmain","BK1515","BK0060","BK0183"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":0.0006},{"period":"3month","weight":-0.0227},{"period":"6month","weight":-0.041},{"period":"1year","weight":0.107},{"period":"ytd","weight":0.013}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}